Larry Robbins is the manager of Glenview Capital Management, a hedge fund with assets under management of over $25B.
Robbins added Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to his portfolio in the most recent quarter. Just today, Teva received approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) for once-daily COPAXONE 20 mg injection to prevent a relapse of multiple sclerosis. In Japan, the product will be commercialized by Takeda Pharmaceutical Company Limited (Takeda). Of the 14 analysts who have recently rated Teva Pharmaceuticals, 13 have rated it as a Buy, in line with Robbins’ moves, and only 1 has rated it as a Hold; no analyst has given a Sell rating to the stock.
In the most recent quarter, Robbins increased his holdings in Google Inc (NASDAQ:GOOGL) by 61.35%. Of late, Google has been in the news for its Alphabet restructuring. The new company structure will include core Google, which is the ads, search and YouTube business, as well as the company’s other experimental moonshot businesses. Out of 33 analysts who have recently rated the stock, 31 have rated it as a Buy and 2 have rated it as a Hold; none of the analysts have recommended to Sell the stock.
Not of the Robbins’ latest moves were bullish. Robbins reduced his holdings in Anthem Inc (NYSE:ANTM), a health benefit company. On September 17th, the company reaffirmed its FY15 EPS outlook of more than $9.55 per share, which includes over $0.45 per share of net unfavourable adjustment items. In July 2015, Anthem agreed to by Cigna Corp. for $48.4 billion. The deal is expected to reshape the health insurance sector. Based on price targets set by 2 analysts rating the company over the past 12 months, the average price target for the stock is $167.50; an 18.03% upside over current levels.
In the last quarter alone, Robbins’ hedge fund made an average return of 2.10%. In the last three years, his hedge fund has earned an average annualized return of 23.35%.
[Image Courtesy of TimesofIsrael.com]